Compare NUVL & BIRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NUVL | BIRK |
|---|---|---|
| Founded | 2017 | 1774 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 8.5B |
| IPO Year | 2021 | 2023 |
| Metric | NUVL | BIRK |
|---|---|---|
| Price | $123.50 | $44.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 14 |
| Target Price | ★ $134.75 | $61.43 |
| AVG Volume (30 Days) | ★ 4.2M | 2.4M |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.71 |
| Revenue Next Year | $1,239.49 | $14.30 |
| P/E Ratio | ★ N/A | $17.48 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $71.14 | $31.33 |
| 52 Week High | $123.69 | $53.53 |
| Indicator | NUVL | BIRK |
|---|---|---|
| Relative Strength Index (RSI) | 66.42 | 53.27 |
| Support Level | $97.99 | $40.81 |
| Resistance Level | $123.62 | $45.80 |
| Average True Range (ATR) | 0.58 | 2.27 |
| MACD | 0.66 | -0.43 |
| Stochastic Oscillator | 99.45 | 29.83 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.